Trinity Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Trinity Biotech plc
TRIB Stock  USD 0.68  0.01  1.49%   
Trinity Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Trinity Biotech's valuation are provided below:
Gross Profit
21.4 M
Profit Margin
(0.52)
Market Capitalization
12.5 M
Enterprise Value Revenue
1.7558
Revenue
61.6 M
We have found one hundred twenty available fundamental trend indicators for Trinity Biotech plc, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Trinity Biotech plc current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of July 31, 2025, Market Cap is expected to decline to about 345.4 M. In addition to that, Enterprise Value is expected to decline to about 449.8 M

Trinity Biotech Total Revenue

79.16 Million

Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Total Revenue of 79.2 M or Gross Profit of 35.1 M, as well as many indicators such as Price To Sales Ratio of 0.24, Dividend Yield of 0.0095 or Days Sales Outstanding of 89.17. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
  
Build AI portfolio with Trinity Stock
Check out the analysis of Trinity Biotech Correlation against competitors.

Trinity Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets142.5 M103.3 M160.8 M
Slightly volatile
Short and Long Term Debt Total105.8 M100.8 M81.5 M
Slightly volatile
Total Current Liabilities23.4 M32.1 M24.4 M
Slightly volatile
Property Plant And Equipment Net4.4 M4.6 M8.4 M
Slightly volatile
Accounts Payable10.1 M6.8 M11.9 M
Pretty Stable
Cash4.9 M5.2 M33.5 M
Slightly volatile
Non Current Assets Total72.7 M62.2 M80 M
Slightly volatile
Cash And Short Term Investments4.9 M5.2 M33.5 M
Slightly volatile
Net Receivables17.2 M14.6 M19 M
Very volatile
Common Stock Shares Outstanding18.9 M18 M10.2 M
Very volatile
Liabilities And Stockholders Equity142.5 M103.3 M160.8 M
Slightly volatile
Non Current Liabilities Total111.7 M106.4 M68.6 M
Slightly volatile
Inventory26 M19.4 M25.9 M
Pretty Stable
Total Liabilities145.4 M138.5 M93.7 M
Slightly volatile
Total Current Assets69.8 M41.1 M80.9 M
Slightly volatile
Short Term Debt2.4 M2.5 M8.4 M
Pretty Stable
Intangible Assets42.2 M37.5 M43.1 M
Pretty Stable
Common Stock Total Equity994.6 K1.4 M1.1 M
Slightly volatile
Property Plant And Equipment Gross74.2 M70.6 M27.8 M
Slightly volatile
Common Stock4.4 M4.2 M1.6 M
Slightly volatile
Long Term Debt46.5 M87.8 M52.5 M
Slightly volatile
Property Plant Equipment9.6 M5.3 M9.3 M
Slightly volatile
Other Liabilities6.2 M5.6 M8.4 M
Very volatile
Current Deferred Revenue187.2 K197 K814.8 K
Pretty Stable
Other Assets4.7 M5 M21.4 M
Pretty Stable
Deferred Long Term Liabilities15.1 M15.9 M37.2 M
Slightly volatile
Short and Long Term Debt179.6 K189 K23.4 M
Very volatile
Long Term Debt Total74.5 M89.8 M94.7 M
Slightly volatile
Capital Surpluse12.9 M14.6 M15.9 M
Slightly volatile
Capital Lease Obligations11.8 M12.8 M7.2 M
Slightly volatile
Non Current Liabilities Other1.1 M2.1 M1.2 M
Slightly volatile
Net Invested Capital67.5 M52.8 M115.6 M
Slightly volatile
Capital Stock4.4 M4.2 M1.7 M
Slightly volatile

Trinity Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.5 M1.9 M3.4 M
Very volatile
Total Revenue79.2 M61.6 M82 M
Pretty Stable
Gross Profit35.1 M21.4 M35.9 M
Pretty Stable
Other Operating Expenses77.8 M82.7 M77.1 M
Slightly volatile
Cost Of Revenue44 M40.1 M46.1 M
Slightly volatile
Total Operating Expenses33.8 M42.6 M31 M
Slightly volatile
Interest Expense12.6 M12 M6.2 M
Slightly volatile
Selling General Administrative24.1 M28.8 M25.6 M
Slightly volatile
Research Development5 M4.5 M4.3 M
Slightly volatile
Selling And Marketing Expenses23.6 M29 M30.3 M
Very volatile
Non Recurring37.2 M37.6 M44 M
Slightly volatile
Reconciled Depreciation2.6 M1.9 M4.1 M
Slightly volatile

Trinity Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.5 M3.7 M36.8 M
Slightly volatile
Depreciation3.5 M1.9 M3.4 M
Very volatile
Capital Expenditures10 M10.1 M13 M
Slightly volatile
End Period Cash Flow4.9 M5.2 M33.6 M
Slightly volatile
Stock Based Compensation1.4 M1.3 M1.4 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.240.25684.3372
Slightly volatile
Dividend Yield0.00950.01680.0154
Slightly volatile
Days Sales Outstanding89.1786.596779.9367
Pretty Stable
Average Payables3.3 M3.8 M3.3 M
Slightly volatile
Stock Based Compensation To Revenue0.01220.02140.016
Pretty Stable
Capex To Depreciation3.825.39623.5572
Very volatile
EV To Sales6.356.689387.107
Slightly volatile
Inventory Turnover3.322.07052.14
Pretty Stable
Days Of Inventory On Hand164176193
Very volatile
Payables Turnover8.295.87067.1047
Slightly volatile
Sales General And Administrative To Revenue0.210.240.2565
Pretty Stable
Average Inventory14.2 M22.9 M23.8 M
Very volatile
Research And Ddevelopement To Revenue0.07130.07380.0572
Pretty Stable
Capex To Revenue0.140.16350.1645
Slightly volatile
Cash Per Share0.01370.01440.4003
Slightly volatile
Payout Ratio0.20.210.2308
Very volatile
Days Payables Outstanding66.9762.173959.3773
Slightly volatile
Intangibles To Total Assets0.30.49710.3738
Pretty Stable
Current Ratio1.221.28133.973
Slightly volatile
Receivables Turnover5.94.21494.7535
Pretty Stable
Capex Per Share0.530.56042.7472
Slightly volatile
Average Receivables13.8 M15.9 M16.7 M
Pretty Stable
Revenue Per Share0.160.17140.8311
Slightly volatile
Interest Debt Per Share0.340.31380.6106
Slightly volatile
Debt To Assets1.020.97550.5359
Slightly volatile
Graham Number0.50.521.2744
Slightly volatile
Operating Cycle229263271
Very volatile
Days Of Payables Outstanding66.9762.173959.3773
Slightly volatile
Dividend Payout Ratio0.20.210.2308
Very volatile
Long Term Debt To Capitalization1.751.66870.7452
Slightly volatile
Total Debt To Capitalization1.611.53640.7346
Slightly volatile
Quick Ratio0.640.67772.7661
Slightly volatile
Cash Ratio0.150.1611.7691
Slightly volatile
Days Of Inventory Outstanding164176193
Very volatile
Days Of Sales Outstanding89.1786.596779.9367
Pretty Stable
Fixed Asset Turnover7.1713.320711.4584
Slightly volatile
Debt Ratio1.020.97550.5359
Slightly volatile
Price Sales Ratio0.240.25684.3372
Slightly volatile
Asset Turnover0.70.59590.5843
Slightly volatile
Gross Profit Margin0.330.34830.4038
Pretty Stable

Trinity Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap345.4 M363.6 M1.3 B
Slightly volatile
Enterprise Value449.8 M473.5 M1.3 B
Slightly volatile

Trinity Fundamental Market Drivers

Cash And Short Term Investments5.2 M

Trinity Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
4th of July 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Trinity Biotech Financial Statements

Trinity Biotech stakeholders use historical fundamental indicators, such as Trinity Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Trinity Biotech's assets and liabilities are reflected in the revenues and expenses on Trinity Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Trinity Biotech plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue197 K187.2 K
Total Revenue61.6 M79.2 M
Cost Of Revenue40.1 M44 M
Stock Based Compensation To Revenue 0.02  0.01 
Sales General And Administrative To Revenue 0.24  0.21 
Research And Ddevelopement To Revenue 0.07  0.07 
Capex To Revenue 0.16  0.14 
Revenue Per Share 0.17  0.16 
Ebit Per Revenue(0.34)(0.33)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:
How To Invest In Trinity
Details
Is Trinity Stock a good investment?
Details
What is Trinity Biotech's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Trinity Biotech Correlation against competitors.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(1.80)
Revenue Per Share
3.427
Quarterly Revenue Growth
0.181
Return On Assets
(0.11)
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY